BMO Capital Markets gave Halozyme (HALO -0.64%) an upgrade today, pushing the company's price target up from $4 to an incredible $12, which has shares up 15%. In the following video, Motley Fool health care analyst David Williamson takes us through BMO's thought process for an upgrade and Halozyme's upcoming catalysts.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Is Halozyme Back?
By Dave Williamson and Max Macaluso
–
Jan 14, 2013 at 3:50PM
NASDAQ: HALO
Halozyme Therapeutics
Market Cap
$7B
Today's Change
(-0.64%) -$0.34
Current Price
$52.81
Price as of June 20, 2025, 4:00 p.m. ET
Can this pharma company make a comeback?
David Williamson owns shares of Pfizer. Follow him on Twitter @MotleyDavid. Max Macaluso has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Halozyme Therapeutics
HALO
$52.81
(-0.64%)
$0.34
Pfizer
PFE
$23.98
(0.40%)
$0.10
Roche Holding AG
RHHBY
$39.20
(-1.06%)
$0.42
Baxter International
BAX
$29.99
(0.64%)
$0.19
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Halozyme Therapeutics, inc (HALO) Q3 2021 Earnings Call Transcript
Halozyme Therapeutics, inc (HALO) Q2 2021 Earnings Call Transcript
Halozyme Therapeutics Inc (HALO) Q1 2021 Earnings Call Transcript
Would Halozyme Make a Good Warren Buffett Stock?
Are Biotech Stocks a Good Hedge Against Higher Inflation?
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.